Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib versus physician's choice chemotherapy in recurrent clear cell ovarian or endometrial carcinoma
NL-OMON47688Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nintedanib in clear cell ovarian cancer and clear cell endometrial carcinoma (CCEC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: progression-free survival. Started Aug 2017; status: completed.
02
Drugs
nintedanib
03
Conditions
clear cell ovarian cancerclear cell endometrial carcinoma (CCEC)
Beyond the preview
Go deeper on NL-OMON47688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47688.